N/A N=130 Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction
Esophageal Carcinoma
Primary: Overall Survival — 12; 11; 13 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer
Stage T3-4NxM0 Gastric Cancer
Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants
Phase 3 N=15 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
Gastric Cancer
Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months
Phase 2 N=39 Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
Gastric Cancer
Primary: Grade 3 or Higher Toxicity Incidence on Step 1 — 65.8 percentage of participants
Phase 2 N=30 Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
Gastric Cancer · Stomach Cancer
Primary: Clinical Response Rate of an Induction Regimen Consisting of Irinotecan, Cisplatin and Cetuximab — 40 percentage of paticipants
Phase 2 N=96 Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer (AGC): Randomized Trial
Gastric Cancer
Primary: Response Rate — 28.9; 26.1 percentage of participants
Phase 2 N=53 Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer
Gastric Cancer
Primary: Percentage of Participants With Objective Response (Objective Response Rate) — 32.1; 67.9 percentage of responders
Phase 2 N=60 Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Phase 2 N=39 Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
Adenocarcinoma of the Gastroesophageal Junction · Diffuse Adenocarcinoma of the Stomach · Intestinal Adenocarcinoma of the Stomach
Primary: Response Rates (RR) in Metastatic Gastric/GE Junction Tumors — 2; 9; 3; 16 participants
Phase 2 N=41 Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)
Gastric Cancer
Primary: Disease Control Rate — 9 Participants
Phase 2 N=54 RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment
Stomach Neoplasm
Primary: Progression-free Survival Rate at 4-month (16 Weeks) — 18.4 percentage of participants
Phase 2 N=112 Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage
Gastric Cancer · Pancreatic Cancer
Primary: Number of Study Participants With Adequate Percutaneous Lavage Specimen Collection — 70; 2; 4 Participants
Phase 2 N=17 A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer
Recurrent Gastric Cancer · Stage IV Gastric Cancer
Primary: Response Rate — 0 percentage of patients responding
Phase 1 N=20 TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
Gastric Adenocarcinoma · GastroEsophageal Cancer
Primary: Percentage of Participants With Progression-free Survival at 6 Months — 40 percent of participants
Phase 2 N=27 Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology
Gastric Adenocarcinoma · Esophagogastric Junction · Gastric Cancer
Primary: Overall Survival (OS) — 11.96 Months
N/A N=60 Perianastomotic Drain After Gastrectomy (DRAG)
Gastric Cancer
Primary: a) Number of Participants With High Pain Levels (Using the Visual Analog Scale) — 31; 3 Participants
Phase 2 N=80 Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: RR — 15 Participants
Phase 3 N=1,053 A Safety and Efficacy Study in Patients With Gastric Cancer
Gastric Cancer
Primary: Median Survival — 8.6; 7.9 Months — p=0.1983
Phase 2 N=34 Docetaxel and Epirubicin in Advanced Gastric Cancer
Stomach Neoplasms
Primary: Overall Survival — 13.4 month
Phase 3 N=855 Trial of Adjuvant Chemotherapy for Gastric Cancer
Stomach Cancer
Primary: Relapse-free Survival Rate — 67.0; 64.9 percentage of participants
Phase 2 N=55 Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
Gastric Adenocarcinoma · Stage II Gastric Cancer · Stage III Gastric Cancer
Primary: Histological Response Determined by FDG Uptake Correlates — 2; 3; 38 participants
Phase 2 N=58 Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
Stomach Cancer · Gastric Cancer
Primary: Complete Pathologic Response Rate — 14 percentage of participants
Phase 2 N=35 Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stomach Cancer · Gastric (Stomach) Cancer · Neoplasm of Cardioesophageal Junction
Primary: Progression-Free Survival (PFS) — 9 Participants
Phase 2 N=69 Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer
Neoplasm, Gastric
Primary: Objective Best Tumor Response — 1; 15; 22; 24 participants
Phase 2 N=21 Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP
Advanced Gastric Cancer
Primary: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) — 3 participants
Phase 2 N=18 Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Gastric Adenocarcinoma · Esophageal Adenocarcinoma · Metastasis
Primary: Best Objective Response Rate (bORR) — 61; 50 Percentage of participants
Phase 2 N=39 FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Gastro-Esophageal Junction Adenocarcinoma · Gastric Cancer
Primary: Objective Response Rate — 15 Participants
Phase 2 N=98 S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction
Esophageal Cancer
Primary: Pathological Complete Response — 26 participants
Phase 2 N=52 Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer
Stomach Neoplasms
Primary: Percentage of Participants With Overall Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors (RECIST) — 15.4 percentage of participants
Phase 2 N=190 A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer
Advanced Gastric Cancer
Primary: Objective Response Rate (ORR) by Investigator — 4.3; 5.0; 13.2; 0 Percent of participants